New combo therapy targets Hard-to-Treat cancers

NCT ID NCT03983954

First seen Jan 04, 2026 · Last updated May 22, 2026 · Updated 17 times

Summary

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measuring how well the drugs shrink tumors. This study is not a cure, but aims to control disease in cancers like breast, ovarian, lung, and others.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • All India Institute of Medical Sciences

    New Delhi, New Delhi, 110029, India

  • Basavatarakam Indo-American Cancer Hospital & Research Institute

    Hyderabad, Telangana, 500034, India

  • National Cancer Institute

    Jhajjar, Haryana, 124105124105, India

  • PMCH (Pacific Medical College & Hospital)

    Udaipur, Rajasthan, 313001, India

  • Rabin Medical Center

    Petah Tikva, Israel

  • Rambam Medical Center

    Haifa, 3109601, Israel

  • Shalby Hospital

    Ahmedabad, Gujarat, 380015, India

  • Sheba Medical Center

    Ramat Gan, 52621, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 6423906, Israel

Conditions

Explore the condition pages connected to this study.